Search
Oruka Therapeutics Inc
ORKAAdd to Watchlist
87.430USD
-7.120-7.53%
Market hours 09/23, 14:08（ET）
5.27BMarket Cap
LossP/E TTM
About Oruka Therapeutics Inc Company
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Oruka Therapeutics Inc Profile
Ticker SymbolORKA
Company nameOruka Therapeutics Inc
IPO dateJul 21, 2000
CEOKlein (Lawrence Otto)
Number of employees28
Security typeOrdinary Share
Fiscal year-endJul 21
Address855 Oak Grove Ave.
CityMENLO PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94025
Phone16506067910
Websitehttps://orukatx.com/
Ticker SymbolORKA
IPO dateJul 21, 2000
CEOKlein (Lawrence Otto)
Company Executives of Oruka Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence Otto Klein, Ph.D.
Dr. Lawrence Otto Klein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
442.81K
-0.55%
Dr. Lawrence Otto Klein, Ph.D.
Dr. Lawrence Otto Klein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
442.81K
-0.55%
Ms. Laura Sandler
Ms. Laura Sandler
Chief Operating Officer
Chief Operating Officer
235.48K
-0.38%
Ms. Laura Sandler
Ms. Laura Sandler
Chief Operating Officer
Chief Operating Officer
235.48K
-0.38%
Dr. Cameron Turtle, Ph.D.
Dr. Cameron Turtle, Ph.D.
Independent Director
Independent Director
108.32K
+21.31%
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Independent Director
Independent Director
38.74K
-90.34%
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Independent Director
Independent Director
38.74K
-90.34%
Mr. Arjun Agarwal
Mr. Arjun Agarwal
Senior Vice President - Finance, Treasurer
Senior Vice President - Finance, Treasurer
11.57K
-9.44%
Mr. Arjun Agarwal
Mr. Arjun Agarwal
Senior Vice President - Finance, Treasurer
Senior Vice President - Finance, Treasurer
11.57K
-9.44%
Dr. Joana Goncalves, M.D.
Dr. Joana Goncalves, M.D.
Chief Medical Officer
Chief Medical Officer
1.01K
-93.39%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence Otto Klein, Ph.D.
Dr. Lawrence Otto Klein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
442.81K
-0.55%
Dr. Lawrence Otto Klein, Ph.D.
Dr. Lawrence Otto Klein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
442.81K
-0.55%
Ms. Laura Sandler
Ms. Laura Sandler
Chief Operating Officer
Chief Operating Officer
235.48K
-0.38%
Ms. Laura Sandler
Ms. Laura Sandler
Chief Operating Officer
Chief Operating Officer
235.48K
-0.38%
Dr. Cameron Turtle, Ph.D.
Dr. Cameron Turtle, Ph.D.
Independent Director
Independent Director
108.32K
+21.31%
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Independent Director
Independent Director
38.74K
-90.34%
FAQs
Who are the top five shareholders of Oruka Therapeutics Inc?
The top five shareholders of Oruka Therapeutics Inc are: Dr. Lawrence Otto Klein, Ph.D.
How many institutions hold shares of Oruka Therapeutics Inc (ORKA)?
As of 2026Q1, 266 institutions hold shares of Oruka Therapeutics Inc, with a combined market value of approximately 56.79M, accounting for 98.54% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 6980689.00.